- 英文名称
- pyripyropene A
- 分子式
- C31H37NO10
- 分子量
- 583.63
- 中文别名
- 化合物 T12592; 化合物 PYRIPYROPENE A; 吡喃平A; (3S,4R,4aR,6S,6aS,12R,12aS,12bS)-4-(乙酰氧基甲基)-12-羟基-4,6a,12b-三甲基-11-氧代-9-(吡啶-3-基)-1,3,4,4a,5,6,6a,12,12a,12b-十氢-2H,11H-苯并[f]吡喃并[4,3-b]二苯并-3,6-二基二乙酸酯; FO 1289A; 2H,11H-Naphtho[2,1-b]pyrano[3,4-e]pyran-11-one, 3,6-bis(acetyloxy)-4-[(acetyloxy)methyl]-1,3,4,4a,5,6,6a,12,12a,12b-decahydro-12-hydroxy-4,6a,12b-trimethyl-9-(3-pyridinyl)-, (3S,4R,4aR,6S,6aS,12R,12aS,12bS)-; Pyripropen A; (3S,4R,4aR,6S,6aS,12R,12aS,12bS)-4-(acetoxymethyl)-12-hydroxy-4,6a,12b-trimethyl-11-oxo-9-(pyridin-3-yl)-1,3,4,4a,5,6,6a,12,12a,12b-decahydro-2H,11H-benzo[f]pyrano[4,3-b]chromene-3,6-diyl diacetate
- 用途
- 作为高效选择性SOAT2/ACAT2抑制剂，IC50值0.07 µM，体内减轻高胆固醇血症和动脉粥样硬化；体外对HUVECs有抗增殖活性（IC50 1.8 µM），抑制VEGF诱导的HUVECs迁移和管形成；体内抑制肝ACAT2活性，降低血浆胆固醇等，在动脉粥样硬化模型中减少病变面积。
